Application of Tumor Burden Score for predicting conversion outcome in patients with initially unresectable colorectal liver metastases after first-line systemic therapy

1. Bray, F, Ferlay, J, Soerjomataram, I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.
Google Scholar | Crossref | Medline2. Zarour, LR, Anand, S, Billingsley, KG, et al. Colorectal cancer liver metastasis: evolving paradigms and future directions. Cell Mol Gastroenterol Hepatol 2017; 3: 163–173.
Google Scholar | Crossref | Medline3. Jones, RP, Kokudo, N, Folprecht, G, et al. Colorectal liver metastases: a critical review of state of the art. Liver Cancer 2016; 6: 66–71.
Google Scholar | Crossref | Medline4. Adam, R, Wicherts, DA, de Haas, RJ, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 2009; 27: 1829–1835.
Google Scholar | Crossref | Medline | ISI5. Adam, R, Delvart, V, Pascal, G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644–657; discussion 657–658.
Google Scholar | Crossref6. Lam, VW, Spiro, C, Laurence, JM, et al. A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol 2012; 19: 1292–1301.
Google Scholar | Crossref | Medline7. Lu, ZH, Peng, JH, Wang, FL, et al. Bevacizumab with preoperative chemotherapy versus preoperative chemotherapy alone for colorectal cancer liver metastases: a retrospective cohort study. Medicine 2016; 95: e4767.
Google Scholar | Crossref | Medline8. Adam, R, Kitano, Y. Multidisciplinary approach of liver metastases from colorectal cancer. Ann Gastroenterol Surg 2019; 3: 50–56.
Google Scholar | Crossref | Medline9. Huiskens, J, van Gulik, TM, van Lienden, KP, et al. Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG). BMC Cancer 2015; 15: 365.
Google Scholar | Crossref | Medline | ISI10. Tomasello, G, Petrelli, F, Ghidini, M, et al. FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis. JAMA Oncol 2017; 3: e170278.
Google Scholar | Crossref | Medline11. Sasaki, K, Morioka, D, Conci, S, et al. The Tumor Burden Score: a new ‘metro-ticket’ prognostic tool for colorectal liver metastases based on tumor size and number of tumors. Ann Surg 2018; 267: 132–141.
Google Scholar | Crossref | Medline12. Oshi, M, Margonis, GA, Sawada, Y, et al. Higher tumor burden neutralizes negative margin status in hepatectomy for colorectal cancer liver metastasis. Ann Surg Oncol 2019; 26: 593–603.
Google Scholar | Crossref | Medline13. Sasaki, K, Margonis, GA, Andreatos, N, et al. The prognostic utility of the ‘Tumor Burden Score’ based on preoperative radiographic features of colorectal liver metastases. J Surg Oncol 2017; 116: 515–523.
Google Scholar | Crossref | Medline14. Lin, JZ, Peng, JH, Zhao, YX, et al. Early recurrence in patients undergoing curative resection of colorectal liver oligometastases: identification of its clinical characteristics, risk factors, and prognosis. J Cancer Res Clin Oncol 2018; 144: 359–369.
Google Scholar | Crossref | Medline15. Therasse, P, Arbuck, SG, Eisenhauer, EA, et al. New guidelines to evaluate the response to treatment in solid Tumors. J Natl Cancer I 2000; 92: 205–216.
Google Scholar | Crossref | Medline16. Rubino, M, Pragnell, MVC. Guidelines for reporting case series of tumours of the colon and rectum. Tech Coloproctol 1999; 3: 93–97.
Google Scholar | Crossref17. Xu, J, Fan, J, Qin, X, et al. Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastases (version 2018). J Cancer Res Clin Oncol 2019; 145: 725–736.
Google Scholar | Crossref | Medline18. Ren, L, Zhu, D, Benson, AB, et al. Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). Eur J Surg Oncol 2020; 46: 955–966.
Google Scholar | Crossref | Medline19. Van Cutsem, E, Cervantes, A, Adam, R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386–1422.
Google Scholar | Crossref | Medline | ISI20. Folprecht, G, Grothey, A, Alberts, S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16: 1311–1319.
Google Scholar | Crossref | Medline | ISI21. Okuno, M, Hatano, E, Nishino, H, et al. Does response rate of chemotherapy with molecular target agents correlate with the conversion rate and survival in patients with unresectable colorectal liver metastases? A systematic review. Eur J Surg Oncol 2017; 43: 1003–1012.
Google Scholar | Crossref | Medline22. Bokemeyer, C, Bondarenko, I, Hartmann, JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011; 22: 1535–1546.
Google Scholar | Crossref | Medline | ISI23. Van Cutsem, E, Kohne, CH, Hitre, E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. New Engl J Med 2009; 360: 1408–1417.
Google Scholar | Crossref | Medline | ISI24. Van Cutsem, E, Kohne, CH, Lang, I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011–2019.
Google Scholar | Crossref | Medline | ISI25. Garcia-Alfonso, P, Ferrer, A, Gil, S, et al. Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents. Target Oncol 2015; 10: 453–465.
Google Scholar | Crossref | Medline26. Margonis, GA, Sasaki, K, Gholami, S, et al. Genetic And Morphological Evaluation (GAME) score for patients with colorectal liver metastases. Br J Surg 2018; 105: 1210–1220.
Google Scholar | Crossref | Medline27. Marques, RP, Duarte, GS, Sterrantino, C, et al. Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2017; 118: 54–62.
Google Scholar | Crossref | Medline28. Montagnani, F, Chiriatti, A, Turrisi, G, et al. A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity. Colorectal Dis 2011; 13: 846–852.
Google Scholar | Crossref | Medline29. Leal, F, Ferreira, FP, Sasse, AD. FOLFOXIRI regimen for metastatic colorectal cancer: a systematic review and meta-analysis. Clin Colorectal Cancer 2017; 16: 405–409.
Google Scholar | Crossref | Medline30. Tosi, F, Magni, E, Amatu, A, et al. Effect of KRAS and BRAF mutations on survival of metastatic colorectal cancer after liver resection: a systematic review and meta-analysis. Clin Colorectal Cancer 2017; 16: e153–e163.
Google Scholar | Crossref | Medline31. Tsilimigras, DI, Ntanasis-Stathopoulos, I, Bagante, F, et al. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: a systematic review of the current evidence. Surg Oncol 2018; 27: 280–288.
Google Scholar | Crossref | Medline32. Yamashita, S, Chun, YS, Kopetz, SE, et al. Biomarkers in colorectal liver metastases. Br J Surg 2018; 105: 618–627.
Google Scholar | Crossref | Medline33. Zimmitti, G, Shindoh, J, Mise, Y, et al. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. Ann Surg Oncol 2015; 22: 834–842.
Google Scholar | Crossref | Medline

留言 (0)

沒有登入
gif